Methods
This was an umbrella review of systematic reviews/meta-analysis
conducted using Medline (OVID), Embase, Scopus, Cochrane library and
medRxiv from inception to 1st February 2021.
Systematic reviews with meta-analysis that evaluated the effect of
ACEIs/ARBs on COVID-19 related clinical outcomes were eligible. Studies’
quality was appraised using the AMSTAR 2 Critical Appraisal Tool. Data
were analysed using the random-effects modelling including several
sub-group analyses. Heterogenicity was assessed using
I2 statistic. The study protocol was registered in
PROSPERO (CRD42021233398).